Federal
Register Notices > Notices
of Application - 2004 >
Cerilliant Corporation
FR Doc 04-23053 [Federal Register: October 14, 2004 (Volume 69,
Number 198)] [Notices] [Page 61043-61044] From the Federal Register
Online via GPO Access [wais.access.gpo.gov] [DOCID:fr14oc04-100]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to 21 CFR
1301.33(a), this is notice that on July 6, 2004,
Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas
78664, made application by renewal to the Drug Enforcement
Administration (DEA) for registration as a bulk manufacturer of the
basic classes of controlled substances listed:
[[Page 61044]]
DRUG |
SCHEDULE |
Cathinone (1235) |
I |
Methcathinone (1237) |
I |
N-Ethylamphetamine (1475) |
I |
N,N-Dimethylamphetamine (1480) |
I |
Aminorex (1585) |
I |
4-Methylaminorex (cis isomer) (1590) |
I |
Gamma hydroxybutyric acid (2010) |
I |
Methaqualone (2565) |
I |
Alpha-Ethyltryptamine (7249) |
I |
Lysergic acid diethylamide (7315) |
I |
Tetrahydrocannabinols (7370) |
I |
Mescaline (7381) |
I |
3,4,5-Trimethoxyamphetamine (7390) |
I |
4-Bromo-2,5-dimethoxyamphetamine (7391) |
I |
4-Bromo-2,5-dimethoxyphenethylamine (7392) |
I |
4-Methyl-2,5-dimethoxyamphetamine (7395) |
I |
2,5-Dimethoxyamphetamine (7396) |
I |
2,5-Dimethoxy-4-ethylamphetamine (7399) |
I |
3,4-Methylenedioxyamphetamine (7400) |
I |
5-Methoxy-3,4-methylenedioxyamphetamine (7401) |
I |
N-Hydroxy-3,4-methylendioxyamphetamine (7402) |
I |
3,4-Methylendioxy-N-ethylamphetamine (7404) |
I |
3,4-Methylenedioxymetham- phetamine (7405) |
I |
4-Methoxyamphetamine (7411) |
I |
Bufotenine (7433) |
I |
Diethyltryptamine (7434) |
I |
Dimethyltryptamine (7435) |
I |
Psilocybin (7437) |
I |
Psilocyn (7438) |
I |
Acetyldihydrocodeine (9051) |
I |
Benzylmorphine (9052) |
I |
Codeine-N-oxide (9053) |
I |
Dihydromorphine (9145) |
I |
Heroin (9200) |
I |
Hydromorphinol (9301) |
I |
Methyldihydromorphine (9304) |
I |
Morphine-N-oxide (9307) |
I |
Normorphine (9313) |
I |
Pholcodine (9314) |
I |
Acetylmethadol (9601) |
I |
Allylprodine (9602) |
I |
Alphacetylmethadol except levo-alphacetylmethadol
(9603) |
I |
Alphameprodine (9604) |
I |
Alphamethadol (9605) |
I |
Betacetylmethadol (9607) |
I |
Betameprodine (9608) |
I |
Betamethadol (9609) |
I |
Betaprodine (9611) |
I |
Hydroxypethidine (9627) |
I |
Noracymethadol (9633) |
I |
Norlevorphanol (9634) |
I |
Normethadone (9635) |
I |
Trimeperidine (9646) |
I |
Phenomorphan (9647) |
I |
Para-Fluorofentanyl (9812) |
I |
3-Methylfentanyl (9813) |
I |
Alpha-Methylfentanyl (9814) |
I |
Acetyl-alpha-methylfentanyl (9815) |
I |
Beta-hydroxyfentanyl (9830) |
I |
Beta-hydroxy-3-methylfentanyl (9831) |
I |
Alpha-Methylthiofentanyl (9832) |
I |
3-Methylthiofentanyl (9833) |
I |
Thiofentanyl (9835) |
I |
Amphetamine (1100) |
II |
Methamphetamine (1105) |
II |
Phenmetrazine (1631) |
II |
Methylphenidate (1724) |
II |
Ambobarbital (2125) |
II |
Pentobarbital (2270) |
II |
Secobarbital (2315) |
II |
Glutethimide (2550) |
II |
Nabilone (7379) |
II |
1-Phenylcyclohexylamine (7460) |
II |
Phencyclidine (7471) |
II |
1-Piperidinocyclohexane- carbonitrile (8603) |
II |
Alphaprodine (9010) |
II |
Cocaine (9041) |
II |
Codeine (9050) |
II |
Dihydrocodeine (9120) |
II |
Oxycodone (9143) |
II |
Hydromorphone (9150) |
II |
Diphenoxylate (9170) |
II |
Benzoylecgonine (9180) |
II |
Ethylmorphine (9190) |
II |
Hydrocodone (9193) |
II |
Levomethorphan (9210) |
II |
Levorphanol (9220) |
II |
Isomethadone (9226) |
II |
Meperidine (9230) |
II |
Methadone (9250) |
II |
Methadone-intermediate (9254) |
II |
Dextropropoxyphene, bulk (non-dosage forms) (9273) |
II |
Morphine (9300) |
II |
Thebaine (9333) |
II |
Levo-alphacetylmethadol (9648) |
II |
Oxymorphone (9652) |
II |
Noroxymorphone (9668) |
II |
Racemethorphan (9732) |
II |
Alfentanil (9737) |
II |
Sufentanil (9740) |
II |
Fentanyl (9801) |
II |
The company plans to manufacture small quantities of the listed
controlled substances to make reference standards for distribution to
their customers. Any other such applicant and any person who is
presently registered with DEA to manufacture such a substance may file
comments or objections to the issuance of the proposed registration
pursuant to 21 CFR
1301.33(a).
Any such comments or objections may be
addressed, in quintuplicate, to the Deputy Assistant Administrator,
Office of Diversion Control, Drug Enforcement Administration, United
States Department of Justice, Washington, DC 20537, Attention: DEA
Federal Register Representative (CCD) and must be filed no later than
December 13, 2004.
Dated: September 28, 2004.
William J. Walker,
Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration.
[FR Doc. 04-23053 Filed 10-13-04; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
Back to
Top
Registration
Support
Toll Free Number: 1-800-882-9539
ARCOS
| Career Opportunities | Chemical Program |
Controlled
Substance Schedules | Drugs and
Chemicals of Concern
Electronic Commerce Initiatives | | Federal Register
Notices | Import Export | Links
| Meetings
and Events | NFLIS
Offices &
Directories | On-Line Forms & Applications |
Program
Description | Publications
|
Questions & Answers | Quotas
Reports Required by 21 CFR | Title 21 Regulations & Codified
CSA
Contact Us | Home
| Hot
Items | Site Map | Search | What's New
|